Valtronic, contract manufacturer of miniaturized electronic products for trusted medical device partners, announces that it is partnering with Synapse Biomedical to commercialize a fully implantable version of the neurostimulation technology upon which Synapse Biomedical was founded.
The Oberlin-based company is in the process of licensing the third-generation diaphragm pacing technology from Case Western Reserve University, and is working with several international partners to make the project a success. This fully implantable version will feature leads that deliver electricity directly to the diaphragm, and no longer will protrude from the skin.
The project is being funded by a $3 million grant from the Ohio Third Frontier economic development program. Several of the partners — Including Valtronic — plan to provide matching funds. Synapse will commercialize the technology in Asia with the help of another partner, USCI Japan Ltd.
Synapse already sells the second-generation technology. The NeuRx Diaphragm Pacing System is best known for helping the late Superman actor Christopher Reeve breathe without a ventilator.
Before the company can sell the new technology, however, it will need to receive approval from regulators in the United States, Europe and Japan.
Skyscraper 1

Skyscraper 3
